Tolaney SM, Goel S, Nadal J, Denys H, et al. Overall survival and exploratory biomarker analyses of abemaciclib plus trastuzumab with or without fulvestrant vs trastuzumab plus chemotherapy in HR+, HER2+ metastatic breast cancer patients. Clin Cancer Res 2023 Oct 31. doi: 10.1158/1078-0432.CCR-23-1209.
PMID: 37906649